QIAGEN (QGEN)
(Delayed Data from NYSE)
$44.45 USD
+0.89 (2.04%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $44.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.45 USD
+0.89 (2.04%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $44.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.
Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics
by Zacks Equity Research
QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.
QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
Qiagen Poised on Fundamentals, Expansion Plans on Track
by Zacks Equity Research
On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).